Cerus Corporation [CERS] shares are up more than 79.46% this year and recently increased 0.02% or $0.15 to settle at $7.34. CERS has a short ratio of 6.48. This implies that the market is currently less bullish on the outlook for CERS.
On 4, December 2020, Cerus Corporation Announces Presentation of Study Results with INTERCEPT-treated COVID-19 Convalescent Plasma at the American Society of Hematology Annual Meeting. According to news published on Yahoo Finance, Cerus Corporation (Nasdaq: CERS) today announced the oral presentation of a clinical study: “Efficacy of COVID-19 Pathogen Inactivated Convalescent Plasma for Patients with Moderate to Severe Acute COVID-19: A Case Matched Control Study,” presented by Dr. Nina Khanna of the University Hospital of Basel, Switzerland, at the American Society of Hematology Annual Meeting, on Saturday, December 5, 2020, at 2:45 pm/EST. This presentation reviews data on the efficacy of INTERCEPT-treated COVID-19 convalescent plasma (CCP) to treat COVID-19 pneumonia patients.
Analyst Birdseye View:
The most recent analyst activity for Cerus Corporation [NASDAQ:CERS] stock was on June 16, 2020, when it was Resumed with an Overweight rating from Cantor Fitzgerald, which also raised its 12-month price target on the stock to $9. Before that, on October 08, 2020, BTIG Research Recapitulated a Buy rating and elevated its amount target to $9. On February 26, 2020, BTIG Research Initiated a Buy rating and boosted its price target on this stock to $7. On November 13, 2019, BTIG Research Upgrade a Buy rating and increased its price target to $7. On August 28, 2019, Stifel Initiated a Buy rating. On August 23, 2019, Stephens Resumed an Overweight rating. On January 05, 2018, Cantor Fitzgerald Resumed an Overweight rating. BTIG Research elevated its amount target by recapitulating a higher weight for this stock.
In the past 52 weeks of trading, this stock has oscillated between a low of $2.71 and a peak of $7.94. Right now, the middling Wall Street analyst 12-month amount mark is $9.50. At the most recent market close, shares of Cerus Corporation [NASDAQ:CERS] were valued at $7.34. According to the average price forecast, investors can expect a potential return of 2.11%.
Cerus Corporation [NASDAQ:CERS] most recently reported quarterly sales of 23.61 billion, which represented growth of 28.10%. This publicly-traded organization’s revenue is $369,189 per employee, while its income is -$280,488 per employee. This company’s Gross Margin is currently 64.30%, its Operating Margin is -56.40%, its Pretax Margin is -75.69, and its Net Margin is -75.97. Continuing to look at profitability, this corporation’s Return on Assets, Equity, Whole Principal & invested Principal is sitting at -43.31, -100.65, -56.15 and -64.36 respectively.
If looking now at the Principal structure of this organization, it shows its whole liability to the whole Principal at 53.04 and the whole liability to whole assets at 38.93. It shows enduring liability to the whole principal at 47.59 and enduring liability to assets at 0.35 while looking for an extended time period.
Readers are usually of view to make a close observation to the indicators that support and make resistance before moving to any particular stock. As of now, the company’s stock is sitting at 7.17 points at 1st support level, the second support level is making up to 6.99. But as of 1st resistance point, this stock is sitting at 7.61 and at 7.87 for 2nd resistance point.
Cerus Corporation [CERS] reported its earnings at -$0.08 per share in the fiscal quarter closing of 9/29/2020. The Analysts for Wall Street were expecting to report its earnings at -$0.1/share signifying the difference of 0.02 and 20.00% surprise value. Comparing the previous quarter ending of 6/29/2020, the stated earnings were -$0.09 calling estimates for -$0.11/share with the difference of 0.02 depicting the surprise of 18.20%.
Important Ratio’s To Watch
Meanwhile, turning our focus to liquidity, the Current Ratio for Cerus Corporation [NASDAQ:CERS] is 3.80. Likewise, the Quick ratio is also the same, showing Cash ratio at 1.70. Now if looking for a valuation of this stock’s amount to sales ratio it’s 6.29 and it’s amount to book ratio is 10.67.
The most recent insider trade was by Swisher Daniel N JR, Director, and it was the sale of 10000.0 shares on Nov 17. Green Kevin Dennis, the Chief Financial Officer, completed a sale of 32928.0 shares on Nov 10. On Aug 24, Benjamin Richard J, Chief Medical Officer, completed a sale of 100000.0 shares.